Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Bayer
INDICATIONS [/za_1164.html#1] [/za_1164.html#1] [/za_1164.html#1] CONTRA-INDICATIONS [/za_1164.html#1] [/za_1164.html#1] DOSAGE [/za_1164.html#1] [/za_1164.html#1] SIDE-EFFECTS [/za_1164.html#1] [/za_1164.html#1] [/za_1164.html#1] PREGNANCY [/za_1164.html#1] [/za_1164.html#1] OVERDOSE [/za_1164.html#1] IDENTIFICATION [/za_1164.html#1] [/za_1164.html#1] PATIENT INFORMATION GLUCOBAY® 50, 100 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): GLUCOBAY ® 50, 100 TABLETS COMPOSITION: GLUCOBAY 50 tablets contain 50 mg ACARBOSE GLUCOBAY 100 tablets contain 100 mg acarbose PHARMACOLOGICAL CLASSIFICATION: A 21.2 Oral hypoglycaemics PHARMACOLOGICAL ACTION: GLUCOBAY is a competitive inhibitor of intestinal alpha-glucosidases with maximum specific inhibitory activity against sucrose . Under the influence of GLUCOBAY, the digestion of starch and sucrose into absorbable monosaccharides in the small intestine is dose-dependently delayed. In diabetic subjects, this results in a lowering of postprandial hyperglycaemia. GLUCOBAY has no stimulatory action on the pancreas. Treatment with GLUCOBAY also results in a reduction of fasting blood glucose and to modest changes in levels of glycosylated haemoglobin (HbA 1 , HbA 1c ). The changes may be a reduction or reduced deterioration in HbA 1 or HbA 1c levels, depending upon the patient's clinical status and disease progression. These parameters are affected in a dose- dependent manner by GLUCOBAY. Following oral administration, only 1-2% is absorbed. INDICATIONS: GLUCOBAY is indicated for the treatment of non-insulin dependent diabetes mellitus (NIDDM) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents. CONTRA-INDICATIONS: Known hypersensitivity to acarbose or any of the excipients, use in c Read the complete document